Commentary

Video

The Impact of the Ponatinib FDA Approval in Newly Diagnosed Ph+ ALL

Author(s):

Ibrahim Aldoss, MD, City of Hope Comprehensive Cancer Center,Elias Jabbour, MD, MD Anderson Cancer Center

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the impact of the FDA approval of ponatinib for the treatment of newly diagnosed patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Related Videos
Minoo Battiwalla, MD, MS
Chad Tang, MD
Idoroenyi Amanam, MD
Amrita Krishnan, MD, executive medical director, Hematology, director, Judy and Bernard Briskin Multiple Myeloma Center, professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
Idoroenyi Amanam, MD
Justin Kaner, MD
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Minoo Battiwalla, MD, MS, director, Blood Cancer Outcomes Research, Sarah Cannon Research Institute, TriStar Medical Group
Saro H. Armenian, DO, MPH
A panel of 3 experts on nasopharyngeal carcinoma
Related Content
Jorge Cortes, MD, of Georgia Cancer Center
October 21st 2024

New Global Hematology Journal Strives to Feature Innovative and Adaptable Research

Ravi Salgia, MD, PhD, professor, chair, Department of Medical Oncology & Therapeutics Research, Arthur & Rosalie Kaplan Chair in Medical Oncology & Therapeutics Research, City of Hope
September 2nd 2024

Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLC

Shyam A. Patel, MD, PhD, University of Massachusetts Chan Medical School
October 16th 2024

Donor Clonal Hematopoiesis May Predict Post-Transplant Relapse and Outcomes in Hematologic Malignancies

Oncology Unplugged
August 21st 2024

Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC

Chad Tang, MD
October 15th 2024

Prospective Trials Could Refine Potential Roles for Radiation in Advanced RCC

Eric Jonasch, MD, physician, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
October 14th 2024

NKT2152 Generates Responses in Heavily Pretreated Advanced ccRCC